Drug Discovery Today

Drug Discovery Today





Editor::Stephen Carney





Go to Journal Website

Personal Print Journal

Subscription Details

Estimated Delivery Time

In Stock

USD 369.00


Subscription Details

ScienceDirect Subscription

  • Access for 5 users
  • Access to 4 years of archives

USD 5,444.80

Print Journal

Subscription Details

Estimated Delivery Time

In Stock

USD 5,446.00
Buying for Institutions
Terms & Conditions

Additional Subscription Help


Aims & Scope

Drug Discovery Today delivers informed and highly current reviews for the discovery community. The magazine addresses not only the rapid scientific developments in drug discovery associated technologies but also the management, commercial and regulatory issues that increasingly play a part in how R&D is planned, structured and executed.

Features include comment by international experts, news and analysis of important developments, reviews of key scientific and strategic issues, overviews of recent progress in specific therapeutic areas and conference reports.
Coverage includes:
Novel therapeutic strategies
High-throughput screening
Therapeutic targets
Combinatorial chemistry, parallel synthesis and library design
Drug delivery
• Advances in key compound classes and therapeutic areas
Genomics and proteomics
Automation and technology
Virtual chemistry
Business strategy
Clinical trials
and other aspects of drug discovery.

Ethics in Publishing: General Statement

The Editor(s) and Publisher of this Journal believe that there are fundamental principles underlying scholarly or professional publishing. While this may not amount to a formal 'code of conduct', these fundamental principles with respect to the authors' paper are that the paper should: i) be the authors' own original work, which has not been previously published elsewhere, ii) reflect the authors' own research and analysis and do so in a truthful and complete manner, iii) properly credit the meaningful contributions of co-authors and co-researchers, iv) not be submitted to more than one journal for consideration, and v) be appropriately placed in the context of prior and existing research. Of equal importance are ethical guidelines dealing with research methods and research funding, including issues dealing with informed consent, research subject privacy rights, conflicts of interest, and sources of funding. While it may not be possible to draft a 'code' that applies adequately to all instances and circumstances, we believe it useful to outline our expectations of authors and procedures that the Journal will employ in the event of questions concerning author conduct. With respect to conflicts of interest, the Publisher now requires authors to declare any conflicts of interest that relate to papers accepted for publication in this Journal. A conflict of interest may exist when an author or the author's institution has a financial or other relationship with other people or organizations that may inappropriately influence the author's work. A conflict can be actual or potential and full disclosure to the Journal is the safest course. All submissions to the Journal must include disclosure of all relationships that could be viewed as presenting a potential conflict of interest. The Journal may use such information as a basis for editorial decisions and may publish such disclosures if they are believed to be important to readers in judging the manuscript. A decision may be made by the Journal not to publish on the basis of the declared conflict.

For more information, please refer to: click here

Submission to Drug Discovery Today is by invitation only. If you are interested in submitting an article please first send us a proposal with a brief description of the main theme of the article (approx. 100 - 200 words), listing the article type and if possible some key references. Information on how to submit a proposal can be found at:click here


Scientists, managers and other professionals in the pharmaceutical and biotechnology sectors, and academic centres focusing on related research. These will include organic, bioorganic and bioinorganic chemists, biochemists, pharmacologists and pharmaceu

Abstracting and Indexing

BIOSIS, Biochemistry and Biophysics Citation Index, CAB Abstracts, Chemical Abstracts, Current Contents, EMBASE, International Pharmaceutical Abstracts, Life Science Collection, MEDLINE®, Science Citation Index, Scisearch, Scopus
Editor: Stephen Carney , Advisory Editorial Board: Jürgen Bajorath Rheinische Friedrich-Wilhelms-Universität Bonn, Bonn, Germany, David Brayden University College Dublin, Dublin, Ireland, Paul Caron Vertex Pharmaceuticals Inc, Cambridge, MA, USA, David Cavalla Numedicus Limited, Cambridge, England, UK, David Clark Argenta Discovery Ltd., Harlow, UK, Dalia Cohen Rosetta Genomics, North Brunswick, NJ, USA, Donald Daley Argenta Discovery Ltd., Harlow, UK, Sean Ekins Jenkintown, PA, USA, Hans-Peter Fischer GeneData AG, Basel, Switzerland, Peter Ghazal University of Edinburgh, Edinburgh, UK, Christopher M. Hill Organon Laboratories Ltd., Newhouse, UK, Nick Hird Takeda Chemical Industries, Ltd., Osaka, Japan, Enoch Huang Pfizer Global Research and Development, Cambridge, MA, USA, Thomas Joos Eberhard-Karls-Universität Tübingen, Reutlingen, Germany, Vincent H.L. Lee Chinese University of Hong Kong, Shatin, N.T., Hong Kong, David Lewin Yale University School of Medicine, New Haven, CT, USA, Christopher A. Lipinski Melior Discovery, Inc., Exton, PA, USA, Lorenz Mayr Novartis Pharma AG, Basel, Switzerland, Nicholas Meanwell Bristol-Myers Squibb Pharmaceutical (U.S.A.), Wallingford, CT, USA, Bilikallahalli Muralidhara Medimmune LLC (AstraZeneca), Mountain View, CA, USA, Mark Murcko Vertex Pharmaceuticals Inc, Cambridge, MA, USA, Fajun Nan Chinese Academy of Sciences (CAS), Shanghai, China, Pradeep Nathan University of Cambridge, Cambridge, England, UK, Gitte Neubauer Cellzome, Heidelberg, Germany, Eric Neumann Teranode Corporation, Seattle, WA, USA, Tim Peakman UK Biobank, Stockport, Cheshire, UK, Norton Peet North Andover, MA, USA, Manuel Peitsch Novartis Pharma AG, Basel, Switzerland, Kurt Rasmussen Eli Lilly and Company, Indianapolis, IN, USA, Janice Reichert Tufts Center for the Study of Drug Development, Boston, MA, USA, John Reidhaar-Olson F. Hoffmann-La Roche Ltd., Nutley, NJ, USA, Mike Romanos GlaxoSmithKline, Stevenage, UK, Ray Rowe University of Bradford, Bradford, West Yorkshire, UK, Andreas Russ University of Oxford, Oxford, UK, Esther Schmid Pfizer Global Research and Development, Sandwich, UK, Jonathan Sheldon InforSense Ltd., London, UK, Michael Snyder Stanford University, Stanford, CA, USA, Susie Stephens Eli Lilly and Company, Indianapolis, IN, USA, Robert Strausberg J. Craig Venter Institute, Rockville, MD, USA, Donny Strosberg The Scripps Research Institute, Jupiter, FL, USA, Yuichi Sugiyama University of Tokyo, Tokyo, Japan, David Szymkowski Xencor, Inc., Monrovia, CA, USA, Nick Terrett Ensemble Therapeutics, Cambridge, MA, USA, Vladimir Torchilin Northeastern University, Boston, MA, USA, Mark Whittaker Evotec OAI, Milton, Abingdon, UK, Hans Winkler Johnson & Johnson, Beerse, Belgium, Limsoon Wong National University of Singapore (NUS), Singapore, Singapore, X.F. Steven Zheng UMDNJ/Robert Wood Johnson Medical School, Piscataway, NJ, USA
Shop with Confidence

Free Shipping around the world
▪ Broad range of products
▪ 30 days return policy

Contact Us

Author Services

Prepare your Article for submission
Translation Services
English Language Editing

Celebrate your publication success
Article Offprints, Journal Issues, Article/Cover Posters, Create Your Own Book

Additional Services
Mobile Apps,Special Content Offerings,and more...